Although biotech stocks are highly speculative, they offer investors tremendous opportunities. As 2022 draws to a close, we take a look at some of the healthcare stocks we profiled that delivered triple-digit gains.
Headline
Published Date
Published Price
Maximum Price Since Publication
Last Closing Price
Max Gain %
TRVI - Trevi Completes Enrollment In PRISM Trial; Data Expected In Q2
Feb. 1
$0.70
$4.68
$2.24
569%
APDN - APDN Soars On News Of Initiating Analytical Validation Of Diagnostic Test For Monkeypox Virus
Aug. 2
$1.33
$7.35
$1.45
453%
BEAT - Will FDA's Decision Be Music To BEAT's Ears?
Jun. 16
$1.24
$6.74
$5.85
444%
NRSN - What's Making News At NeuroSense?
Feb. 28
$1.76
$8.18
$1.51
365%
COGT - Will Cogent Biosciences Reach The APEX And PEAK?
May. 16
$4.02
$18.07
$11.23
350%
RYTM - Will Rhythm Hit The Right Notes?
Feb. 18
$7.52
$30.98
$26.38
312%
VERU - Veru Gains On Efficacy Of COVID-19 Drug Candidate In Phase 3 Trial
Apr. 11
$5.99
$24.55
$5.83
310%
IMUX - Immunic's EMPhASIS Trial Data Published In Peer Reviewed Journal
Jun. 15
$3.24
$11.76
$1.19
263%
AMLX - FDA Panel Snubs Amylyx Pharma's Experimental ALS Drug
Mar. 31
$11.68
$39.78
$37.04
241%
DICE - DICE: Hit Or Miss?
$13.99
$45.99
$32.53
229%
IMRA - Will IMARA Ace The Ardent And Forte Trials?
Mar. 14
$1.61
$5.26
$3.84
227%
AKRO - Will Akero's HARMONY Hit The Goals?
Mar. 7
$15.34
$48.24
$43.60
214%
SIGA - SIGA Rises 15% On Getting FDA Approval For IV Formulation Of TPOXX
May. 19
$8.76
$26.99
$8.02
208%
CELU - Celularity's NK Cell Therapy Awarded FDA's Fast Track Status For Yet Another Indication
Jan. 18
$4.34
$13.19
$1.54
204%
CVRX - Will CVRx Q1 Results Beat Or Lag Estimates?
Apr. 25
$4.89
$14.70
$13.94
201%
STIM - Neuronetics Expects 5% To 12% Revenue Growth In 2022
May. 13
$2.28
$6.73
$6.20
195%
NERV - Minerva Seeks FDA Approval For Roluperidone In Treating Negative Symptoms Of Schizophrenia
Aug. 24
$5.39
$15.27
$3.20
183%
NVCT - What's Making News At Nuvectis?
Mar. 29
$7.50
$20.92
$7.59
179%
CTIC - CTI BioPharma Gets Speedy FDA Approval For Myelofibrosis Drug
Mar. 1
$2.83
$7.80
$5.64
176%
ABOS - INTERCEPT-AD Data Could Reveal ABOS' Acumen
Apr. 20
$4.01
$10.97
$5.72
174%
MHUA - Meihua International - Getting Back On Track?
Sep. 20
$5.52
$14.94
$8.83
171%
BIVI - Can BioVie Turn The Tables This Year?
Feb. 11
$3.41
$9.10
167%
IMGO - Imago BioSciences Awaits Results Of Essential Thrombocythemia Trial
May. 15
$14.39
$35.89
$35.87
149%
MYOV - Myovant/Pfizer's Myfembree Awaits FDA Word - Go Or No Go?
Apr. 12
$10.81
$26.93
$26.84
VTYX - Ventyx Biosciences Awaits VTX958 Trial Data
Aug. 11
$17.19
$41.29
$27.11
140%
NUVL - Will Nuvalent's ARROS-1 Hit The Target?
Aug. 10
$17.00
$40.43
$31.56
138%
AXSM - Axsome Therapeutics Soars On FDA's Labeling Of AXS-05 For Depressive Disorder
Jun. 27
$34.62
$80.87
$77.85
134%
PRVB - Will Teplizumab Be A Game Changer In The Diabetes Space?
Aug. 5
$4.23
$9.85
$9.04
133%
GOVX - GeoVax Issued Patent For Cancer Vaccine
Mar. 22
$1.85
$4.30
$0.74
132%
DBTX - Decibel Therapeutics Is Being Heard And Here's Why
Jun. 28
$2.50
$5.78
$2.76
131%
ANIX - Anixa's Ovarian Cancer CAR-T Therapy To Be Discussed At International Workshop On Apr.29
Apr. 6
$2.72
$6.25
$4.62
130%
XFOR - X4 Pharma To Present Neutropenia Trial Data Today
Sep. 27
$1.05
$2.41
$0.99
ATNM - Actinium Pharma Inks Deal With Immedica For Lead Drug Candidate Iomab-B
$6.59
$15.12
$11.05
129%
LNTH - Lantheus Teams Up With Palette Life To Promote Prostate Cancer Diagnostic Imaging Agent
Feb. 24
$38.28
$87.47
$53.51
DBVT - DBV Technologies To Provide Corporate Update Today
Mar. 3
$3.43
$1.31
127%
VIGL - Vigil Neuroscience Notches Triple-digit Gains
Jul. 21
$7.45
$16.77
$12.10
125%
MGNX - MacroGenics Braces For A Busy 2H 2022
Jul. 20
$7.57
$6.22
121%
OLK - Olink Optimistic Of Robust Growth In 2022
May. 24
$11.32
$24.93
$22.52
120%
SONX - Will Sonendo's Q4 Results Bring A Smile To Investors?
$3.15
$6.84
$2.90
117%
PRPH - ProPhase Soars As Q1 Results Crush Estimates
$7.03
$15.25
$10.38
ORMP - Here's Why You Need To Keep An Eye On ORMP
May. 3
$5.65
$12.18
$8.64
116%
RXRX - After SYCAMOR, Recursion Pharma To Initiate POPLAR-NF2 In Q2
Apr. 26
$6.66
$14.18
$9.34
113%
ACLX - Arcellx At The ASCO...
Jun. 3
$12.66
$26.91
$21.68
MNPR - Will Monopar Make Its VOICE Heard?
May. 18
$2.30
$4.88
$2.62
112%
PRVA - Privia Health Confident About 2022 Growth Prospects
$21.09
$44.64
$23.13
AVEO - AVEO Expects Triple-digit Growth For Kidney Cancer Drug In FY22
Jul. 7
$7.20
$14.95
$14.89
108%
FSTX - Will F-star Therapeutics Shine This Year?
Mar. 17
$3.26
$6.76
$5.32
107%
BLUE - Bluebird Bio - Not In The Pink Of Health?
$4.17
$8.58
$7.84
106%
ALDX - Keep GUARD Over Aldeyra's TRANQUILITY...
Mar. 16
$3.90
$7.99
$6.08
105%
BLFS - BioLife Solutions Expects 34%-42% Revenue Growth In 2022
May. 27
$13.28
$26.96
$19.80
103%
ESPR - Esperion's Q4 Net Product Revenue Jumps 49%; Data Readout Of CLEAR Outcomes Study In Q1, 2023
Feb. 23
$4.36
$8.85
$6.18
PCVX - Vaxcyte - An Ounce Of Prevention Is Worth A Pound Of Cure
Apr. 19
$23.72
$47.67
$43.97
101%
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.